- OpenAI launched GPT-Rosalind, a frontier reasoning model built specifically for drug discovery and life sciences research.
- Moderna, Amgen, and Thermo Fisher Scientific are already using it—days after OpenAI signed a strategic alliance with Novo Nordisk.
- The launch lands two days after Amazon unveiled Amazon Bio Discovery, making AI drug discovery the newest battleground for Big Tech.
OpenAI just entered the drug discovery race with a model named after the woman whose X-ray crystallography helped crack the structure of DNA. GPT-Rosalind—designed to accelerate evidence synthesis, hypothesis generation, and experimental planning—went live Thursday as a research preview in ChatGPT and via API for life science partners. It’s already running workflows at Moderna, Amgen, the Allen Institute, and Thermo Fisher Scientific.
The timing isn’t accidental. OpenAI signed a strategic alliance with Novo Nordisk earlier this week, applying its AI technologies across the Danish pharmaceutical giant’s operations “from drug discovery to commercial,” according to pharmaphorum. That deal alone signals OpenAI’s ambitions in life sciences are anything but experimental—they’re commercial.
Amazon Bio Discovery, which launched just days before GPT-Rosalind, is chasing the same prize. So are NVIDIA BioNeMo, Alphabet’s Isomorphic Labs, and Anthropic, whose CEO just welcomed Novartis chief Vas Narasimhan to the board. The AI drug discovery space now has every major tech company competing to collapse the decade-long timeline from target discovery to clinical trials.
What GPT-Rosalind Actually Does
OpenAI calls GPT-Rosalind a “frontier reasoning model built to support research across biology, drug discovery, and translational medicine.” That’s corporate language for: it reads massive amounts of biomedical literature, finds connections humans miss, and proposes experiments faster than a postdoc on three espressos. The model handles evidence synthesis across thousands of papers, generates and tests hypotheses computationally, and plans experimental workflows that would take human teams weeks to outline.
The real differentiator is integration. GPT-Rosalind plugs directly into Codex—OpenAI’s cloud-based AI software engineering agent—and ships with a free life sciences research plugin that connects to more than 50 scientific tools and data sources. Those span human genetics, functional genomics, protein structure, biochemistry, clinical evidence, and public study databases. “The life sciences field demands precision at every step,” said Sean Bruich, head of AI and data at Amgen. “The questions are highly complex, the data is highly unique, and the stakes are incredibly high.”
For pharma companies, the value proposition is straightforward: compress timelines. Drug development typically takes 10 to 15 years and costs upward of $2.6 billion per approved drug, according to Tufts Center for the Study of Drug Development estimates. If AI models like GPT-Rosalind can shave even a year off the discovery and preclinical phases, the savings multiply across entire pipelines.
The AI Drug Discovery Arms Race Is Officially On
OpenAI isn’t the only company betting big on biology. Amazon’s Bio Discovery platform reportedly cut Memorial Sloan Kettering’s antibody design process from a year to weeks. NVIDIA’s BioNeMo framework has been training drug discovery models since 2023. Alphabet’s DeepMind spun off Isomorphic Labs specifically to apply AlphaFold’s protein structure predictions to drug design. And Anthropic’s growing pharma ties—evidenced by the Novartis board appointment—suggest the company isn’t sitting this one out either.
“This is the first release in our Life Sciences model series, and we view it as the beginning of a long-term commitment to building AI that can accelerate scientific discovery in areas that matter deeply to society, from human health to broader biological research,” said OpenAI. The company plans to expand biological reasoning capabilities, add support for tool-heavy and long-horizon research workflows, and work with scientific institutions to evaluate real-world impact.
Novartis CEO Vas Narasimhan’s addition to Anthropic’s board this week, alongside OpenAI’s Novo Nordisk alliance and Amazon’s Bio Discovery launch, marks a consolidation moment. The pharma industry—which spent years debating whether AI was worth the investment—is now placing multi-billion-dollar bets on every available frontier model.
The model is available as a free research preview in ChatGPT starting today.